Published in BMC Cancer on April 12, 2017
Comprehensive molecular portraits of human breast tumours. Nature (2012) 47.39
Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012. Int J Cancer (2014) 40.30
DNA methylation in cancer: too much, but also too little. Oncogene (2002) 6.96
Promoter hypermethylation and BRCA1 inactivation in sporadic breast and ovarian tumors. J Natl Cancer Inst (2000) 6.38
Chromosomal instability and tumors promoted by DNA hypomethylation. Science (2003) 6.02
Epigenetic gene silencing in cancer: the DNA hypermethylome. Hum Mol Genet (2007) 3.12
DNA methylation and breast carcinogenesis. Oncogene (2002) 3.03
Analysis of adenomatous polyposis coli promoter hypermethylation in human cancer. Cancer Res (2000) 2.99
Role of the p16 tumor suppressor gene in cancer. J Clin Oncol (1998) 2.51
DNA methylation of RASSF1A, HIN-1, RAR-beta, Cyclin D2 and Twist in in situ and invasive lobular breast carcinoma. Int J Cancer (2003) 2.18
Constitutional methylation of the BRCA1 promoter is specifically associated with BRCA1 mutation-associated pathology in early-onset breast cancer. Cancer Prev Res (Phila) (2010) 2.08
Molecular subtypes of breast cancer are associated with characteristic DNA methylation patterns. Breast Cancer Res (2010) 1.97
Promoter hypermethylation in benign breast epithelium in relation to predicted breast cancer risk. Clin Cancer Res (2005) 1.93
Field effect in cancer-an update. Ann Clin Lab Sci (2009) 1.91
Promoter methylation of the PTEN gene is a common molecular change in breast cancer. Genes Chromosomes Cancer (2004) 1.82
Epigenetic silencing and deletion of the BRCA1 gene in sporadic breast cancer. Breast Cancer Res (2006) 1.80
Tumor suppressor gene promoter hypermethylation in serum of breast cancer patients. Clin Cancer Res (2004) 1.62
The epigenetics of breast cancer. Mol Oncol (2010) 1.57
Aberrant methylation of the adenomatous polyposis coli (APC) gene promoter 1A in breast and lung carcinomas. Clin Cancer Res (2001) 1.52
Aberrant promoter hypermethylation and genomic hypomethylation in tumor, adjacent normal tissues and blood from breast cancer patients. Anticancer Res (2010) 1.46
Quantitative, spatial resolution of the epigenetic field effect in prostate cancer. Prostate (2008) 1.46
Changes in CpG islands promoter methylation patterns during ductal breast carcinoma progression. Cancer Epidemiol Biomarkers Prev (2009) 1.43
Epigenetic and genetic alterations of APC and CDH1 genes in lobular breast cancer: relationships with abnormal E-cadherin and catenin expression and microsatellite instability. Int J Cancer (2003) 1.43
Mammary field cancerization: molecular evidence and clinical importance. Breast Cancer Res Treat (2009) 1.40
PTEN promoter is methylated in a proportion of invasive breast cancers. Int J Cancer (2004) 1.33
Detection of breast cancer in nipple aspirate fluid by CpG island hypermethylation. Clin Cancer Res (2004) 1.31
Hypermethylation in histologically distinct classes of breast cancer. Clin Cancer Res (2004) 1.25
Prognostic significance of gene-specific promoter hypermethylation in breast cancer patients. Breast Cancer Res Treat (2011) 1.22
Estrogen receptor alpha, BRCA1, and FANCF promoter methylation occur in distinct subsets of sporadic breast cancers. Breast Cancer Res Treat (2007) 1.22
High quality assessment of DNA methylation in archival tissues from colorectal cancer patients using quantitative high-resolution melting analysis. J Mol Diagn (2009) 1.21
Adenomatous polyposis coli (APC) gene promoter hypermethylation in primary breast cancers. Br J Cancer (2001) 1.21
Frequent aberrant DNA methylation of ABCB1, FOXC1, PPP2R2B and PTEN in ductal carcinoma in situ and early invasive breast cancer. Breast Cancer Res (2010) 1.18
DNA methylation and cancer diagnosis. Int J Mol Sci (2013) 1.18
Promoter methylation and the detection of breast cancer. Cancer Causes Control (2009) 1.18
CpG island hypermethylation of BRCA1 and loss of pRb as co-occurring events in basal/triple-negative breast cancer. Epigenetics (2011) 1.17
BRCA1 promoter methylation is associated with increased mortality among women with breast cancer. Breast Cancer Res Treat (2008) 1.16
Methylated genes as new cancer biomarkers. Eur J Cancer (2009) 1.16
Methylation is less abundant in BRCA1-associated compared with sporadic breast cancer. Ann Oncol (2008) 1.12
p16(INK4a) promoter methylation and protein expression in breast fibroadenoma and carcinoma. Int J Cancer (2005) 1.10
DNA hypermethylation and clinicopathological features in breast cancer: the Western New York Exposures and Breast Cancer (WEB) Study. Breast Cancer Res Treat (2008) 1.10
Hypomethylation of LINE-1 in primary tumor has poor prognosis in young breast cancer patients: a retrospective cohort study. Breast Cancer Res Treat (2012) 1.09
Methylome sequencing in triple-negative breast cancer reveals distinct methylation clusters with prognostic value. Nat Commun (2015) 1.05
Tumor markers in clinical practice: a review focusing on common solid cancers. Med Princ Pract (2012) 1.04
Frequent deletion and methylation in SH3GL2 and CDKN2A loci are associated with early- and late-onset breast carcinoma. Ann Surg Oncol (2008) 1.03
Quantitative DNA methylation analyses reveal stage dependent DNA methylation and association to clinico-pathological factors in breast tumors. BMC Cancer (2013) 1.02
DNA methylation signatures for breast cancer classification and prognosis. Genome Med (2012) 1.01
Quantitative methylation profiling in tumor and matched morphologically normal tissues from breast cancer patients. BMC Cancer (2010) 0.99
DNA methylation profiling of phyllodes and fibroadenoma tumours of the breast. Breast Cancer Res Treat (2010) 0.99
Gene promoter methylation is associated with increased mortality among women with breast cancer. Breast Cancer Res Treat (2009) 0.97
Methylation of estrogen receptor beta promoter correlates with loss of ER-beta expression in mammary carcinoma and is an early indication marker in premalignant lesions. Endocr Relat Cancer (2005) 0.96
Simultaneous CXCL12 and ESR1 CpG island hypermethylation correlates with poor prognosis in sporadic breast cancer. BMC Cancer (2010) 0.96
HER2 in breast cancer: a review and update. Adv Anat Pathol (2014) 0.93
Aberrant p16((INK4a)) methylation is a frequent event in colorectal cancers: prognostic value and relation to mRNA expression and immunoreactivity. J Cancer Res Clin Oncol (2010) 0.93
Methylation profile of triple-negative breast carcinomas. Oncogenesis (2012) 0.93
Field cancerization in mammary carcinogenesis - Implications for prevention and treatment of breast cancer. Exp Mol Pathol (2012) 0.92
Association of aberrant DNA methylation with clinicopathological features in breast cancer. Oncol Rep (2011) 0.92
Applicability of HIN-1, MGMT and RASSF1A promoter methylation as biomarkers for detecting field cancerization in breast cancer. Breast Cancer Res (2015) 0.91
PTEN mutation, methylation and expression in breast cancer patients. Oncol Lett (2013) 0.90
Exploring DNA methylation changes in promoter, intragenic, and intergenic regions as early and late events in breast cancer formation. BMC Cancer (2015) 0.90
Association between frequent CpG island methylation and HER2 amplification in human breast cancers. Carcinogenesis (2009) 0.90
Epigenetic biomarkers: A new perspective in laboratory diagnostics. Clin Chim Acta (2012) 0.87
DNA methylation in the promoter region of the p16 (CDKN2/MTS-1/INK4A) gene in human breast tumours. Br J Cancer (1999) 0.86
Epigenetic field defects in progression to cancer. World J Gastrointest Oncol (2013) 0.86
The epigenetic silencing of the estrogen receptor (ER) by hypermethylation of the ESR1 promoter is seen predominantly in triple-negative breast cancers in Indian women. Tumour Biol (2012) 0.85
Methylation of exon 2 of p16 is associated with late stage oesophageal cancer. Cancer Lett (2000) 0.84
Triapine-mediated ABCB1 induction via PKC induces widespread therapy unresponsiveness but is not underlying acquired triapine resistance. Cancer Lett (2015) 0.84
Alu and LINE-1 hypomethylation is associated with HER2 enriched subtype of breast cancer. PLoS One (2014) 0.83
ESR1 gene promoter region methylation in free circulating DNA and its correlation with estrogen receptor protein expression in tumor tissue in breast cancer patients. BMC Cancer (2014) 0.82
A seven-gene CpG-island methylation panel predicts breast cancer progression. BMC Cancer (2015) 0.82
Promoter methylation of BRCA1 is associated with estrogen, progesterone and human epidermal growth factor receptor-negative tumors and the prognosis of breast cancer: A meta-analysis. Mol Clin Oncol (2015) 0.82
Differential DNA methylation status between breast carcinomatous and normal tissues. Biomed Pharmacother (2014) 0.81
Promoter hypermethylation of tumour suppressor genes (p14/ARF and p16/INK4a): case-control study in North Indian population. Mol Biol Rep (2013) 0.81
Epigenetic alteration of p16 and retinoic acid receptor beta genes in the development of epithelial ovarian carcinoma. Tumour Biol (2014) 0.80
Association of sporadic breast cancer with PTEN/MMAC1/TEP1 promoter hypermethylation. Med Oncol (2010) 0.80
Methylation in benign prostate and risk of disease progression in men subsequently diagnosed with prostate cancer. Int J Cancer (2016) 0.78
Association of promoter methylation of ERα and ERβ with sporadic breast cancer--a study from North India. Tumour Biol (2014) 0.76
Reduced expression of APC-1B but not APC-1A by the deletion of promoter 1B is responsible for familial adenomatous polyposis. Sci Rep (2016) 0.76
Promoter methylation patterns of ABCB1, ABCC1 and ABCG2 in human cancer cell lines, multidrug-resistant cell models and tumor, tumor-adjacent and tumor-distant tissues from breast cancer patients. Oncotarget (2016) 0.76
ESR1 and PGR gene promoter methylation and correlations with estrogen and progesterone receptors in ductal and lobular breast cancer. Asian Pac J Cancer Prev (2014) 0.75